Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (562)	1/28/2005 12:10:44 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 625

Abbott Lab To Appeal Vs Cambridge Antibody Royalty Ruling Friday January 28, 10:12 AM EST LONDON -(Dow Jones)- Abbott Laboratories Inc (ABT) intends to lodge an appeal through the U.K. Court of Appeals in a royalties case against Cambridge Antibody Technology Group PLC after its appeal Friday was rejected by the U.K. High Court. The case involves the level of royalties Abbott is expected to pay Cambridge Antibody for rheumatoid arthritis drug Humira, which the two companies developed together. In December the High Court agreed that Cambridge should receive the level of royalties it demanded. The High Court's Justice Laddie Friday rejected Abbot's appeal of that decision, prompting the company to pursue the case through the Court of Appeals. The High Court was set to decide later Friday whether either company will be compelled to pay the other's costs in the case. At 1453 GMT Cambridge shares were up 0.48%, or 3.50, pence at 738 pence. -By Elena Berton, Dow Jones Newswires; 44-20-7842-9267; elena.berton@ dowjones.com